Hims & Hers Health to Halt Compounded GLP-1 Sales in Landmark Settlement

The decision by Hims & Hers Health to stop selling compounded GLP-1 medications represents a pivotal moment for the telehealth industry and the broader regulatory framework governing drug compounding. For nearly two years, the company capitalized on a regulatory loophole that allows compounding pharmacies to produce versions of patented drugs when they are listed on the FDA’s official shortage list. By offering compounded semaglutide and tirzepatide at a fraction of the cost of branded versions like Wegovy and Zepbound, Hims & Hers saw its valuation soar and its subscriber base expand rapidly. However, this settlement signals that the 'compounding gold rush' is facing a definitive legal and regulatory wall as supply chains for branded manufacturers stabilize.

At the heart of this dispute is Section 503A of the Federal Food, Drug, and Cosmetic Act, which provides a narrow exemption for compounding pharmacies to create 'essentially a copy' of a commercially available drug only during times of shortage. As Novo Nordisk and Eli Lilly have ramped up production capacity, the FDA has begun the process of removing various dosages of these drugs from the shortage list. This shift effectively strips away the legal protection telehealth companies relied on to market compounded alternatives. The settlement reached by Hims & Hers is likely a preemptive move to avoid more punitive damages and a protracted legal battle that could have set an even harsher precedent for the industry.

“

As Novo Nordisk and Eli Lilly have ramped up production capacity, the FDA has begun the process of removing various dosages of these drugs from the shortage list.

From a market perspective, the impact on Hims & Hers is substantial. The company’s weight-loss segment had become a primary driver of its growth narrative, with investors closely watching the conversion of GLP-1 interest into long-term subscriptions. By exiting the compounded market, Hims & Hers must now pivot its strategy toward providing access to branded GLP-1s or alternative weight-loss treatments that do not infringe on existing patents. This transition will likely involve lower margins, as the company will have to navigate the complex world of insurance coverage and pharmacy benefit managers, rather than selling high-margin compounded products directly to consumers.